Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Balicatib in Postmenopausal Osteoporosis
NCT00170911Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2005
- Primary completion
- Dec 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of balicatib in osteoporosis and osteopenia (5 arms), sponsored by Novartis. Primary endpoints: Change of lumbar spine (L1-L4) Bone Mineral Density at 12 months and Safety of 12 month treatment. Started Mar 2005; status: completed.
02
Drugs
balicatib
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on NCT00170911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00170911.